Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Jul 11;78(1):73-81. Epub 2016 May 11.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA.

Purpose: Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that overcome the limitations of camptothecins: chemical instability and camptothecin resistance. Two dosing schedules of the novel indenoisoquinoline, indotecan (LMP400), were evaluated in patients with advanced solid tumors.

Methods: The maximum tolerated dose (MTD), toxicities, and pharmacokinetics of two indotecan drug administration schedules (daily for 5 days or weekly) were investigated. Modulation of TopI and the phosphorylation of histone H2AX (γH2AX) were assayed in tumor biopsies; γH2AX levels were also evaluated in circulating tumor cells (CTCs) and hair follicles to assess DNA damage response.

Results: An MTD of 60 mg/m(2)/day was established for the daily regimen, compared to 90 mg/m(2) for the weekly regimen. The TopI response to drug showed target engagement in a subset of tumor biopsies. Pharmacokinetics profiles demonstrated a prolonged terminal half-life and tissue accumulation compared to topotecan. Dose-dependent decreases in total CTCs were measured in seven patients. Formation of γH2AX-positive foci in CTCs (day 3) and hair follicles (4-6 h) was observed following treatment.

Conclusions: We established the MTD of two dosing schedules for a novel TopI inhibitor, indotecan. Target engagement was demonstrated as Top1 downregulation and γH2AX response. No objective responses were observed on either schedule in this small patient cohort. The principal toxicity of both schedules was myelosuppression; no significant gastrointestinal problems were observed. Increased DNA damage response was observed in CTCs, hair follicles, and a subset of tumor biopsies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2998-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5199138PMC
July 2016
36 Reads

Publication Analysis

Top Keywords

dosing schedules
12
hair follicles
12
tumor biopsies
12
ctcs hair
8
dna damage
8
advanced solid
8
target engagement
8
subset tumor
8
indotecan lmp400
8
patients advanced
8
novel indenoisoquinoline
8
schedules novel
8
schedules
5
biopsies pharmacokinetics
4
pharmacokinetics profiles
4
decreases total
4
engagement subset
4
response drug
4
drug target
4
profiles demonstrated
4

References

(Supplied by CrossRef)

Y Pommier et al.
Nat Rev Cancer 2006

I Kostopoulos et al.
BMC Cancer 2009

J Pawel von et al.
J Clin Oncol 2014

MA Cinelli et al.
J Med Chem 2012

DE Beck et al.
J Med Chem 2014

R Simon et al.
J Natl Cancer Inst 1997

JL Holleran et al.
J Pharm Biomed Anal 2010

RJ Kinders et al.
Clin Cancer Res 2010

TD Pfister et al.
PLoS One 2012

LH Wang et al.
Clin Cancer Res 2010

CE Redon et al.
PLoS One 2010

Similar Publications